Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Lung Neoplasms 11Neoplasm Metastasis 10Carcinoma, Hepatocellular 9Breast Neoplasms 9Pancreatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Advanced Solid Tumors 7Melanoma 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Recurrence 3Multiple Myeloma 3Head and Neck Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Advanced Solid Tumours 3Vulvar Neoplasms 2Vaginal Neoplasms 2Solid Tumor 2

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1atezolizumab 1ZD4054 1Topotecan 1Tiragolumab 1Rosuvastatin Calcium 1Radiotherapy 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Malignancies × durvalumab × Clear all
NCT03394144 2019-06-24

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
11 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡